Filing identity and period
The supplied filing is Cara Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2014. This does not match the request metadata identifying Tvardi Therapeutics, Inc.; verify the issuer and filing before relying on this summary. Financial amounts below are in thousands of dollars unless otherwise stated.
Business context
Cara was a clinical-stage biopharmaceutical company developing CR845, a kappa opioid receptor-targeting drug candidate. Its lead program, I.V. CR845, had completed three Phase 2 acute postoperative pain trials; Oral CR845 was also in development. The company had no products for sale, and substantially all recognized revenue came from license and collaboration arrangements.
Financial results and liquidity
| Metric | Q1 2014 | Q1 2013 |
|---|---|---|
| Revenue | $178 | $0 |
| Research and development expense | $2,201 | $922 |
| General and administrative expense | $1,398 | $588 |
| Operating loss | $(3,421) | $(1,510) |
| Net loss | $(3,383) | $(2,632) |
| Net cash used in operations | $(3,091) | $(1,819) |
Cash and cash equivalents were $67,038 at March 31, 2014, up from $12,357 at December 31, 2013. Current assets were $68,226 and current liabilities $5,753; restricted cash was an additional $700. The company reported $57,772 of net IPO proceeds in financing cash flows. Its equity statement reports $56,247 net of underwriting discounts and offering expenses; the filing explains that IPO costs paid before or remaining unpaid at quarter-end affect the cash-flow presentation. The preferred stock converted to common stock upon the IPO, and no debt is shown on the March 31 balance sheet. Accumulated deficit was $65,839.
Profit margins are not meaningful given the company’s development-stage operations and minimal collaboration revenue. The filing does not report product sales.
Changes versus prior period
- Revenue rose to $178 from none, including $151 of amortized Maruishi upfront-license revenue and $27 from clinical-material sales.
- R&D expense increased $1,279, principally from I.V. CR845 clinical and preclinical work and Oral CR845 tablet development.
- G&A expense increased $810, including higher professional fees, insurance, and IPO-related public and investor relations costs.
- Net loss increased by $751. The comparison was partly offset by the absence of the prior-year $1,129 net interest expense, largely related to convertible notes and related accounting charges.
- The February 2014 IPO raised capital, and outstanding preferred shares converted into common shares. Common shares outstanding rose to 22,592,414 at quarter-end from 4,288,243 at year-end 2013.
Outlook, risks, and other matters
Management expected the March 31 cash balance to fund operations for at least 24 months, without assuming collaboration milestone payments, but cautioned that clinical-trial timing and costs could make cash run out sooner. It expected continued losses and higher expenses, including from planned Phase 3 I.V. CR845 trials. Plans included an FDA End-of-Phase-2 meeting and anticipated Phase 3 initiation in the second half of 2014, topline data from an I.V. abuse-liability study and Oral CR845 tablet Phase 1 trial in the second half of 2014, and an IND filing for uremic pruritus in 2014.
Key risks include clinical and regulatory failure or delay, uncertain commercialization and market acceptance, competition, dependence on collaborators and third-party manufacturers, intellectual-property protection, and the possibility that additional financing may be needed on unfavorable terms or unavailable. Potential Maruishi and CKD milestones and royalties were contingent on development and commercialization and were not assured. Contractual obligations totaled $8,159, mainly operating leases and executive employment agreements. The company reported no material legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls as of March 31, 2014.
Investor facts to verify
- Confirm that this Cara Therapeutics filing—not a Tvardi Therapeutics filing—is the intended document.
- Review the IPO proceeds reconciliation, including offering costs paid before quarter-end and unpaid at quarter-end.
- Assess the assumptions behind management’s stated 24-month cash runway against planned trial scope, timing, and spending.
- Check subsequent progress and actual outcomes for the planned I.V. and Oral CR845 development milestones.
- Review the 2013 Form 10-K risk factors and collaboration agreements for detailed terms and contingencies.